Global analysis puts aging-related disease at center of lifetime health burden

What happened

A peer-reviewed analysis published September 2 in *Nature Aging* reframes the global shift from infectious disease toward chronic illness around a different question: when during life does each disease impose its greatest burden?

Using international mortality, disability and population data, the researchers concluded that aging-related diseases are already the largest global cluster for disability, mortality and overall health loss. When the burden was calculated over the expected lifetime of a newborn, aging-related diseases ranked first in every World Bank income group—including countries whose populations remain relatively young.

The result does not show that aging itself has been treated, or that a particular intervention extends healthspan. It is a population-level classification and modeling study intended to guide research and health-system priorities.

How the analysis worked

The investigators analyzed Global Burden of Disease estimates covering 304 diseases and injuries across 204 countries from 1990 through 2023. They used an unsupervised K-means++ algorithm to group conditions according to the shape of their disability-adjusted life-year burden across age, rather than first labeling diseases as infectious, chronic or biologically caused by aging.

That process produced four clusters: infant, early-adult, later-adult and aging-related diseases. Population structure, life expectancy and survival estimates came from the United Nations World Population Prospects 2024. The researchers also stratified results by World Bank income group.

For lifetime burden, they weighted age-specific years lived with disability and years of life lost by the probability that a newborn would survive to each age. This differs from a snapshot of present-day burden, which can make diseases affecting younger populations appear more prominent simply because more people currently occupy those ages.

Later-life disease dominates expected burden

The analysis found that aging-related diseases were the leading source of years lived with disability in every income group. They were also the largest contributor to current overall disease burden in high- and upper-middle-income countries and ranked second to infant diseases in lower-middle- and low-income countries.

The lifetime calculation changed that picture. Aging-related conditions represented the largest expected combined burden for a newborn in all four income categories. In low-income countries, their modeled lifetime burden only narrowly exceeded that of infant diseases, underscoring that child and infectious-disease priorities have not disappeared.

The authors connected the shift to longer survival. Global life expectancy rose from 58 years in 1973 to more than 73 years in 2023, while the share of people aged 65 or older doubled from roughly 5% in 1970 to about 10% today. The United Nations projects that share to reach 21% by 2073.

Why the model finds “increasing returns”

The researchers simulated permanent reductions in the prevalence of each disease cluster. For aging-related diseases, progressively larger reductions generated more-than-proportional gains in future health-adjusted life-years. A modeled 50% reduction produced about 2.2 times the benefit of a 25% reduction by 2050; complete removal produced about 5.9 times the benefit.

The proposed explanation is demographic and mathematical. Reducing later-life mortality leaves more people alive at ages when aging-related disease is most common. Further reductions then benefit a larger older population, while simultaneous reductions in disability add health to those additional years.

These are scenario results, not forecasts or clinical-effect estimates. The study assumed proportional changes in mortality and disability when prevalence was reduced. It did not identify which prevention programs, medicines or geroscience interventions could produce changes of that magnitude.

What remains uncertain

Global Burden of Disease figures are modeled estimates assembled from data of uneven availability and quality. The disease clusters are statistical, not proof that every condition assigned to the aging-related group shares a biological mechanism. The analysis also used five-year age intervals, did not separate results by sex and projected future burden under simplified assumptions about fertility, income growth and transitions between income groups.

Pandemics, wars, new treatments, unequal healthcare access and changing risk exposures could substantially alter the trajectory. The practical message is therefore about priorities: health systems increasingly need prevention and research that preserve function while reducing later-life disease. The analysis does not establish that targeting a single aging pathway will deliver those population-level gains.